Cyient DLM Q1 FY27 Earnings Call — Analysis (NSE: CYIENTDLM)
Cyient DLM reports highest-ever order book of ₹2,598.9 Cr with Q1 FY27 revenue up 34.3% YoY and PAT more than doubling, while outlining aggressive margin expansion roadmap into AI, robotics and B2S.
The take
Q1FY27 Revenue ₹373.8 Cr ( +34.3% YoY ) . New guidance — Q3FY28 b2s revenue contribution and ma… 250 bps to 300 bps . New story: Record order book and strong book-to-bill .
Results
Revenue ₹373.8 Cr +34.3% YoY; EBITDA margin 10.5% (+147 bps YoY); PAT ₹16.3 Cr +118.2% YoY; order book hits record ₹2,598.9 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹373.8 Cr | +34.3% | yoy · Q1FY27 |
| EBITDA | ₹39.2 Cr | +56.2% | yoy · Q1FY27 |
| EBITDA Margin | 10.5% | +147 bps | yoy · Q1FY27 |
| PAT | ₹16.3 Cr | +118.2% | yoy · Q1FY27 |
| PAT Margin | 4.4% | +168 bps | yoy · Q1FY27 |
| Order Book | ₹2,598.9 Cr | point_in_time · Q1FY27 · as of end-Q1FY27 | |
| Order Intake | ₹551.9 Cr | point_in_time · Q1FY27 · Q1FY27 inflow | |
| Book-to-Bill | 1.5x | none · Q1FY27 · Q1FY27 | |
| Aerospace Revenue Growth (YoY) | 40% | +40% | yoy · Q1FY27 |
| Industrial Revenue Growth (YoY) | 90% | +90% | yoy · Q1FY27 |
| Defence Revenue Growth (YoY) | 35% | +35% | yoy · Q1FY27 |
| MedTech Revenue Growth (YoY) | Flat | +~0% | yoy · Q1FY27 |
| PCBA Revenue Growth (YoY) | 21% | +21% | yoy · Q1FY27 |
| Box Build Revenue Growth (YoY) | 85% | +85% | yoy · Q1FY27 |
Guidance
Management guided book-to-bill ratio to remain around 1.5x for FY27 and set expand-phase EBITDA margin target of 11-13% by FY29.
What management committed to
- [Cyient DLM] will maintain a book-to-bill ratio of around 1.5x for FY27. — 1.5x, FY27
- [Cyient DLM's] EBITDA margin in the Expand phase (FY27-29) will reach 11% to 13%. — 11% to 13%, FY27-FY29
- [Cyient DLM's] EBITDA margin in the Transform phase (FY30 and beyond) will reach 13% to 18%. — 13% to 18%, FY30+
- B2S product revenues will contribute substantially in the next 12 to 18 months, adding 250 bps to 300 bps to consolidated EBITDA margin. — 250 bps to 300 bps, Q3FY28
- Aerospace customers Honeywell and Thales will deliver extraordinary growth in FY27. — FY27
- [Cyient DLM] does not need any additional capex beyond regular annual capex; existing capacity can support 1.75x to 2x of current revenue. — 1.75x to 2x, FY27
- Order intake momentum from Israeli customers will continue in Q2FY27 and beyond. — Q2FY27 onwards
- [Cyient DLM] will secure order intake from AI data centres and robotics sectors in FY27 itself. — FY27
- Semiconductor capital equipment revenue will see growth in the next 6 to 12 months. — Q3FY27-Q4FY27
- [Cyient DLM's] build-to-spec program for the Japanese eVTOL customer (SkyDrive) will enter production in another 12 to 18 months. — Q3FY28
Key themes
Record order book, margin expansion roadmap, new AI/data centre adjacencies
How the narrative shifted
- Record order book and strong book-to-bill: Management highlights highest-ever order backlog of ₹2,598.9 Cr and 1.5x book-to-bill as tangible proof of demand strength and revenue visibility.
- Expansion into AI data centres and robotics: Entry into AI infrastructure and robotics positioned as new high-margin growth vectors that leverage existing capabilities without new capex.
- Margin trajectory through SET phases: Three-phase roadmap (Strengthen, Expand, Transform) aims to lift margins from current 10.5% to 13-18% via mix shift, new sectors, and B2S.
- Aerospace moat and deep OEM relationships: Cyient DLM's entrenched relationships with global aerospace/defence OEMs (Honeywell, Thales) create a durable competitive advantage that is hard to replicate, providing steady growth.
- Supply chain resilience amid geopolitical uncertainty: Management acknowledges ongoing West Asia disruptions but emphasises proactive inventory build-up and alternative sourcing as effective mitigants, ensuring no Q1 impact and minimal Q2 risk.
- Working capital investment for growth: Elevated inventory and negative free cash flow are framed as necessary leading indicators to support robust growth and avoid revenue disruption; management expects normalization once growth stabilises.
- Customer diversification and new logos: New customer acquisitions in industrial and automotive, plus 30% of order intake from logos added in the last 4-6 quarters, are reducing concentration and broadening the base.
Operational commentary
- Order book reached all-time high of ₹2,598.9 Cr; order intake ₹551.9 Cr with 1.5x book-to-bill, driven by both existing customers deepening engagement and new customer additions.
- Added two new logos in industrial and automotive segments, broadening customer base and reducing concentration risk.
- Expanded Build-to-Specifications (B2S) lab footprint from 6,000 sq ft to 15,000 sq ft, providing headroom for product platform development in the Transform phase.
- Completed Nadcap audit for cable harness assembly at Mysore unit, reinforcing aerospace high-reliability positioning and credibility with key OEMs.
- B2S product platforms seeing continued momentum with strong order pipeline from key customers; expected to add 250-300 bps to consolidated EBITDA margins in 12-18 months.
- Leadership team strengthened with appointment of Chief Strategy & Growth Officer Rama Alapati to drive go-to-market and new segment expansion into AI/data centres and robotics.
- Aerospace (+40% YoY) and Industrial (+90% YoY) drove growth; Defence +35% YoY; MedTech flat due to seasonal customer impact; Honeywell Aerospace and Thales anticipated to deliver extraordinary growth this year.
- ITAR-certified facility opening US defence opportunities; early-stage build-to-spec and build-to-print engagements progressing with European and North American defence customers.
- AI data center and robotics entry initiated; sales directors onboarded, existing capacity sufficient (1.75x-2x revenue), no additional capex required beyond regular annual capex.
Analyst Q&A
Q. What is the expected growth CAGR for FY26-29 and how much will AI data center & robotics contribute by FY29? What is the margin delta for B2S?
Management declined to provide specific growth contribution figures, stating internal plans exist; they confirmed B2S will add 250-300 bps to consolidated EBITDA margins in 12-18 months.
Q. Which specific product categories are being targeted in AI data centres and robotics, and what incremental capex is required?
Management said the strategy and sales team are in place, but product specifics will be shared in the next 2-3 quarters; they confirmed no additional capex needed beyond regular annual capex.
Q. Can you provide constant-currency revenue growth for the export business?
CFO noted the company reports in INR and would provide dollar growth figures separately.
Q. Can you provide full-year revenue or order book guidance?
Management indicated similar momentum and book-to-bill ratio of 1.5x for the year, but avoided giving absolute revenue or order book targets.
Q. What is the production timeline for the Japanese eVTOL (SkyDrive) B2S program?
Rajendra stated the program is currently in engineering design and will take another 12 to 18 months to enter production.
Research and educational content only. Not investment advice.